Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd

SHG:600332 China Medical Distribution
Market Cap
$4.88 Billion
CN¥35.79 Billion CNY
Market Cap Rank
#3915 Global
#353 in China
Share Price
CN¥25.46
Change (1 day)
+0.32%
52-Week Range
CN¥24.92 - CN¥27.59
All Time High
CN¥41.57
Categories
Companies in China Medical Distribution
About

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited researches, develops, manufactures, and sells Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials. The company operates through Great Southern TCM, Great Commerce, Great Health, and Other segments. It is also involved in the wholesale, retail, sale, … Read more

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332) - Net Assets

Latest net assets as of September 2025: CN¥39.98 Billion CNY

Based on the latest financial reports, Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332) has net assets worth CN¥39.98 Billion CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥83.17 Billion) and total liabilities (CN¥43.19 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥39.98 Billion
% of Total Assets 48.08%
Annual Growth Rate 13.3%
5-Year Change 33.91%
10-Year Change 334.94%
Growth Volatility 22.46

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd - Net Assets Trend (1997–2024)

This chart illustrates how Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (1997–2024)

The table below shows the annual net assets of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd from 1997 to 2024.

Year Net Assets Change
2024-12-31 CN¥37.77 Billion +2.98%
2023-12-31 CN¥36.68 Billion +9.04%
2022-12-31 CN¥33.64 Billion +7.38%
2021-12-31 CN¥31.33 Billion +11.07%
2020-12-31 CN¥28.21 Billion +8.53%
2019-12-31 CN¥25.99 Billion +12.30%
2018-12-31 CN¥23.14 Billion +20.15%
2017-12-31 CN¥19.26 Billion +9.12%
2016-12-31 CN¥17.65 Billion +103.29%
2015-12-31 CN¥8.68 Billion +9.11%
2014-12-31 CN¥7.96 Billion +13.34%
2013-12-31 CN¥7.02 Billion +66.23%
2012-12-31 CN¥4.22 Billion +8.45%
2011-12-31 CN¥3.90 Billion +6.96%
2010-12-31 CN¥3.64 Billion +7.05%
2009-12-31 CN¥3.40 Billion +5.48%
2008-12-31 CN¥3.22 Billion -2.10%
2007-12-31 CN¥3.29 Billion +11.51%
2006-12-31 CN¥2.95 Billion +5.25%
2005-12-31 CN¥2.81 Billion +6.46%
2004-12-31 CN¥2.64 Billion +1.55%
2003-12-31 CN¥2.60 Billion +7.16%
2002-12-31 CN¥2.42 Billion +6.09%
2001-12-31 CN¥2.28 Billion +52.42%
2000-12-31 CN¥1.50 Billion -0.32%
1999-12-31 CN¥1.50 Billion +7.52%
1998-12-31 CN¥1.40 Billion +7.72%
1997-12-31 CN¥1.30 Billion --

Equity Component Analysis

This analysis shows how different components contribute to Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 2181845030466.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥21.82 Billion 60.76%
Common Stock CN¥1.63 Billion 4.53%
Other Comprehensive Income CN¥3.41 Billion 9.49%
Other Components CN¥9.06 Billion 25.22%
Total Equity CN¥35.90 Billion 100.00%

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Competitors by Market Cap

The table below lists competitors of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd ranked by their market capitalization.

Company Market Cap
Choice Properties Real Estate Investment Trust
PINK:PPRQF
 		$3.04 Billion
Korea Zinc Inc
KO:010130
 		$3.05 Billion
Helmerich and Payne Inc
NYSE:HP
 		$3.05 Billion
Dyno Nobel Ltd
AU:DNL
 		$3.05 Billion
SM Energy Co
NYSE:SM
 		$3.04 Billion
Railway Signal Communication Ltd
SHG:688009
 		$3.04 Billion
Acciona S.A
PINK:ACXIF
 		$3.04 Billion
Chongqing Rural Commercial Bank Co. Ltd
OTCGREY:COGQF
 		$3.04 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 34,919,280,946 to 35,904,528,000, a change of 985,247,054 (2.8%).
  • Net income of 2,835,496,168 contributed positively to equity growth.
  • Dividend payments of 2,250,715,000 reduced retained earnings.
  • Other comprehensive income increased equity by 121,233,447.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥2.84 Billion +7.9%
Dividends Paid CN¥2.25 Billion -6.27%
Other Comprehensive Income CN¥121.23 Million +0.34%
Other Changes CN¥279.23 Million +0.78%
Total Change CN¥- 2.82%

Book Value vs Market Value Analysis

This analysis compares Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.15x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 17.73x to 1.15x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1997-12-31 CN¥1.44 CN¥25.46 x
1998-12-31 CN¥1.55 CN¥25.46 x
1999-12-31 CN¥1.69 CN¥25.46 x
2000-12-31 CN¥1.72 CN¥25.46 x
2001-12-31 CN¥2.68 CN¥25.46 x
2002-12-31 CN¥2.82 CN¥25.46 x
2003-12-31 CN¥3.00 CN¥25.46 x
2004-12-31 CN¥3.01 CN¥25.46 x
2005-12-31 CN¥3.23 CN¥25.46 x
2006-12-31 CN¥3.44 CN¥25.46 x
2007-12-31 CN¥3.77 CN¥25.46 x
2008-12-31 CN¥3.85 CN¥25.46 x
2009-12-31 CN¥4.07 CN¥25.46 x
2010-12-31 CN¥4.36 CN¥25.46 x
2011-12-31 CN¥4.67 CN¥25.46 x
2012-12-31 CN¥3.25 CN¥25.46 x
2013-12-31 CN¥5.35 CN¥25.46 x
2014-12-31 CN¥5.99 CN¥25.46 x
2015-12-31 CN¥6.54 CN¥25.46 x
2016-12-31 CN¥12.36 CN¥25.46 x
2017-12-31 CN¥11.61 CN¥25.46 x
2018-12-31 CN¥13.33 CN¥25.46 x
2019-12-31 CN¥14.88 CN¥25.46 x
2020-12-31 CN¥16.08 CN¥25.46 x
2021-12-31 CN¥17.88 CN¥25.46 x
2022-12-31 CN¥19.72 CN¥25.46 x
2023-12-31 CN¥21.48 CN¥25.46 x
2024-12-31 CN¥22.08 CN¥25.46 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 7.90%
  • The company has moderate efficiency in generating returns from equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 3.78%
  • • Asset Turnover: 0.92x
  • • Equity Multiplier: 2.28x
  • Recent ROE (7.90%) is below the historical average (10.07%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1997 9.58% 3.63% 1.02x 2.58x CN¥-4.88 Million
1998 9.83% 3.66% 1.13x 2.38x CN¥-2.12 Million
1999 9.44% 3.73% 1.14x 2.21x CN¥-7.64 Million
2000 10.46% 3.46% 1.38x 2.19x CN¥6.49 Million
2001 6.73% 2.74% 1.44x 1.70x CN¥-71.16 Million
2002 6.93% 2.67% 1.42x 1.82x CN¥-70.22 Million
2003 5.75% 2.01% 1.48x 1.94x CN¥-103.15 Million
2004 2.27% 0.72% 1.49x 2.12x CN¥-188.73 Million
2005 7.04% 2.04% 1.77x 1.94x CN¥-77.66 Million
2006 8.15% 2.22% 1.89x 1.94x CN¥-51.48 Million
2007 10.95% 2.72% 1.98x 2.03x CN¥29.11 Million
2008 5.84% 5.17% 0.85x 1.32x CN¥-129.99 Million
2009 6.39% 5.44% 0.92x 1.28x CN¥-119.43 Million
2010 7.55% 5.95% 1.00x 1.26x CN¥-86.83 Million
2011 7.60% 5.29% 1.12x 1.28x CN¥-90.63 Million
2012 17.80% 6.04% 1.93x 1.52x CN¥319.38 Million
2013 14.35% 5.57% 1.44x 1.79x CN¥296.87 Million
2014 15.43% 6.35% 1.32x 1.84x CN¥420.21 Million
2015 15.39% 6.80% 1.21x 1.88x CN¥455.27 Million
2016 8.69% 7.53% 0.77x 1.49x CN¥-226.48 Million
2017 10.92% 9.84% 0.74x 1.50x CN¥174.50 Million
2018 15.87% 8.15% 0.82x 2.37x CN¥1.27 Billion
2019 13.19% 4.91% 1.14x 2.35x CN¥770.40 Million
2020 11.15% 4.73% 1.03x 2.29x CN¥300.76 Million
2021 12.80% 5.39% 1.04x 2.28x CN¥813.66 Million
2022 12.37% 5.60% 0.95x 2.33x CN¥760.01 Million
2023 11.61% 5.37% 0.96x 2.25x CN¥563.75 Million
2024 7.90% 3.78% 0.92x 2.28x CN¥-754.96 Million

Industry Comparison

This section compares Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's net assets metrics with peer companies in the Medical Distribution industry.

Industry Context

  • Industry: Medical Distribution
  • Average net assets among peers: $5,061,699,679
  • Average return on equity (ROE) among peers: 3.63%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332) CN¥39.98 Billion 9.58% 1.08x $3.04 Billion
C.Q. Pharmaceutical Holding Co Ltd (000950) $329.08 Million -29.91% 1.75x $539.38 Million
Shenzhen Glory Medical Co Ltd (002551) $2.82 Billion 2.12% 0.68x $266.49 Million
Shandong Realcan Pharmaceutical Co Ltd (002589) $5.69 Billion 0.36% 1.81x $435.98 Million
Qingdao Baheal Medical INC. (301015) $1.50 Billion 18.20% 1.70x $456.67 Million
China Meheco Co Ltd (600056) $382.07 Million 11.69% 1.02x $1.02 Billion
Liaoning Cheng Da Co Ltd (600739) $21.37 Billion 6.77% 0.66x $1.40 Billion
Jointown Pharmaceutical Group Co Ltd (600998) $4.84 Billion 8.53% 2.06x $1.61 Billion
Guangxi Liuzhou Pharm Co Ltd (603368) $3.57 Billion 11.25% 1.12x $667.23 Million